Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Forbes: Can Celery Protect the Brain against Inflammation?; The Center for the Biology of Chronic Disease (CBCD) Reviews a Report
  • USA - English


News provided by

CBCD

Mar 02, 2015, 06:00 ET

Share this article

Share toX

Share this article

Share toX


Rochester, NY (PRWEB) March 02, 2015 -- “Infected with the varicella zoster virus (VZV), which causes shingles? The Center for the Biology of Chronic Disease (CBCD), which tested the formula of Novirin in two post-marketing clinical studies, recommends taking this natural antiviral supplement against the latent virus.” – Greg Bennett, CBCD

We believe the evidence points to the brain protecting properties of celery. We therefore recommend that VZV infected individuals make celery a part of their diet. We also recommend taking Novirin. - Greg Bennett, CBCD

Post this

A plant compound called luteolin, which is found in celery, may reduce brain inflammation, and prevent neuro-degeneration (the progressive loss of structure or function of brain cells, including death of brain cells). (1) As Dr. Saebyeol and colleagues wrote in a study, “Luteolin, a flavonoid found in high concentrations in celery and green pepper, has been shown to reduce production of proinflammatory mediators….” (See PNAS, from 2008) (2) Dr. Saebyeol is from the Integrative Immunology and Behavior Program at the University of Illinois at Urbana - Champaign. “By inhibiting the action of inflammatory cytokines as earlier mentioned, luteolin can prevent the onset of degeneration in the brain.” (1)

This is important since some viruses are known to cause inflammation in the brain. One such virus is the varicella zoster virus (VZV), which causes both chickenpox and shingles. A Dr. Nagel wrote “recent studies have emerged which reveal that VZV infection of the cerebral arteries directly causes pathological vascular remodeling and stroke (VZV vasculopathy).” (See Current Neurology & Neuroscience Reports, published in advance of April 2015) (3) Dr. Nagel is from the University of Colorado Health Sciences Center in Denver, Colorado. In other words, according to Dr. Nagel, the shingles virus directly attacks the arteries in the brain causing inflammation, which can result in brain cell death, and stroke.

Importantly, Dr. Nagel also wrote that “in the past few years, several large epidemiological studies in Taiwan, Denmark, and the U.K. demonstrated that zoster is a risk factor for stroke and that antiviral therapy may reduce this risk.” (3)

Taking an antiviral product against the shingles virus may be vitally important, since another study showed that “adults with zoster have a 30% increased risk of stroke within the following year. Although the exact incidence of stroke caused by VZV is unknown, more than 900,000 people in the United States will develop zoster annually.” (See The Journal of Immunology, from 2012) (4)

“We believe in a comprehensive, positive blend of natural and Western medicines. We believe the evidence points to the brain protecting properties of celery. We therefore recommend that VZV infected individuals make celery a part of their diet. We also recommend taking Novirin, which has a natural formula designed to target the latent VZV.” – Greg Bennett, CBCD

Click to learn more about the latent VZV.

The Center for the Biology of Chronic Disease (CBCD) recommends that VZV infected individuals take Novirin. This natural antiviral supplement has a formula that was designed to help the immune system target the latent form of the Varicella Zoster Virus. The formula was also shown to be effective against herpes viruses in two separate post-marketing clinical studies that followed FDA guidelines.

The formula of Novirin was tested by Hanan Polansky and Edan Itzkovitz from the CBCD. The studies showed that the Novirin formula is effective against the herpes family of viruses. Varicella Zoster is a member of the herpes family. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, “individuals infected with (herpes viruses) … reported a safe decrease in their symptoms following treatment with (the Novirin formula).” (5) The study authors also wrote that, “we observed a statistically significant decrease in the severity, duration, and frequency of symptoms.” (5)

Novirin can be ordered through the product website here: http://www.novirin.com.

Novirin is a natural antiviral dietary supplement. Its formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses.

To date, Novirin is the only natural antiviral product on the market with published clinical studies that support the product's antiviral claims.

The CBCD believes that eating the right foods is just as important as taking a safe and effective, antiviral supplement like Novirin. “Flavonoids, plant polyphenolic compounds abundant in fruits and vegetables, exhibit a wide variety of biological effects, including … anti-inflammatory properties.” (2) The CBCD points out that the formula of Novirin also contains flavanoids such as quercetin.

The CDC notes that the varicella zoster virus (VZV), which is a herpes virus, causes both chickenpox and shingles. “After a person recovers from chickenpox, the virus stays dormant (inactive) in the body. For reasons that are not fully known, the virus can reactivate years later, causing shingles.” (6) Additionally, the CDC adds that “almost 1 out of every 3 people in the United States will develop shingles, also known as zoster or herpes zoster, in their lifetime. There are an estimated 1 million cases of shingles each year in this country. Anyone who has recovered from chickenpox may develop shingles; even children can get shingles. However the risk of shingles increases as you get older. About half of all cases occur in men and women 60 years old or older.” (See the CDC, last reviewed on May 1, 2014) (6)

Are there other treatments currently on the market, which target the Varicella Zoster Virus (VZV)?

Yes there are.

Zostavax is a vaccine that may reduce the risk of developing a shingles outbreak, and decrease the long-term pain from post-herpetic neuralgia (PHN). In adults vaccinated at age 60 years or older, however, protection from the vaccine decreases within the first 5 years after vaccination. (6)

There are also antiviral drugs, such as Zovirax or Valtrex. However, these medications, when effective, only work to shorten the time of the shingles outbreak. They are ineffective against the latent VZV virus. (6)

Novirin is a natural remedy designed to help the immune system target latent herpes viruses, including the VZV. (5)

Interested individuals can view the studies published on the antiviral formula of Novirin here:http://www.scirp.org/journal/PaperInformation.aspx?PaperID=36101#.VNc8leaUf90 and http://www.scirp.org/journal/PaperInformation.aspx?PaperID=44234

Click to learn more about Novirin and shingles.

All orders of Novirin are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:

(1) Forbes.com - Cohen, J. "12 Best Foods To Boost Brain Power." Published February 5, 2015. http://www.forbes.com/sites/jennifercohen/2015/02/05/12-best-foods-to-boost-brain-power/

(2) Saebyeol Jang, Keith W. Kelley,* and Rodney W. Johnson* "Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1." Proc Natl Acad Sci U S A. 2008 May 27; 105(21): 7534–7539 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2396685/

(3) Nagel MA1, Gilden D. "The relationship between herpes zoster and stroke." Curr Neurol Neurosci Rep. 2015 Apr;15(4):534
http://www.ncbi.nlm.nih.gov/pubmed/25712420

(4) Stephanie James,1Alexander Choe,1Igor Traktinskiy,1Maria Nagel,1 and Donald Gilden "Varicella zoster virus can reactivate and infect cerebral adventital fibroblasts, suppressing Jak/STAT and causing stroke." The Journal of Immunology, 2012, 188, 168.35
jimmunol.org/cgi/content/meeting_abstract/188/1_MeetingAbstracts/168.35

(5) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013.
scirp.org/journal/PaperInformation.aspx?PaperID=3610

(6) CDC.gov - "Shingles (Herpes Zoster)" - Prevention & Treatment. Last Reviewed on May 1, 2014.
cdc.gov/shingles/about/prevention-treatment.html

Greg Bennett, CBCD, http://gene-eden-kill-virus.com/, +1 5852509999, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.